Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-P3
- Development stage
- Unknown
- Lead developer
- Peking University First Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
68Ga-P3 is a diagnostic radiopharmaceutical composed of a human prostate-specific membrane antigen (PSMA)-targeting ligand, P3, labeled with the radioisotope gallium-68. It is designed for positron emission tomography (PET) imaging to detect PSMA-expressing lesions, primarily in prostate cancer. The drug binds to PSMA on malignant prostate cells; the radioactive gallium-68 emits positrons that are detected by PET/CT imaging systems, allowing for sensitive and specific localization of tumors. In clinical studies, 68Ga-P3 has demonstrated high sensitivity and specificity for tumor localization and can also be used intraoperatively with fluorescence imaging to guide surgical resection. The agent was initially developed by Peking University First Hospital and is currently in clinical development for use in patients with prostate cancer[1][3].
- Other names
- gallium Ga 68 P3
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 68Ga-P3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-P3.